Molecular Partners Net Income Over Time
| MOLN Stock | CHF 3.60 0.03 0.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Molecular Partners Performance and Molecular Partners Correlation. Molecular |
Cross Equities Net Income Analysis
Compare Molecular Partners and related stocks such as Santhera Pharmaceuticals, Ascom Holding AG, and Addex Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SANN | (28.3 M) | (27.8 M) | (31.4 M) | (5.8 M) | (7.5 M) | 5.9 M | (35.4 M) | (51.5 M) | (54.2 M) | (19 M) | (67.7 M) | (55.5 M) | (71.1 M) | 54.8 M | (42 M) | (37.8 M) | (39.7 M) |
| ASCN | (67.8 M) | 23.1 M | 20.9 M | 36.9 M | 38.5 M | 24.3 M | (145.7 M) | 25.9 M | 21.4 M | 500 K | 6.5 M | 13.5 M | 11 M | 17.4 M | 3.7 M | 3.3 M | 3.2 M |
| ADXN | (20.5 M) | (31.1 M) | (27 M) | (14.5 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | 7.1 M | 8.1 M | 8.5 M |
| EVE | (23.2 M) | (22.5 M) | (16 M) | (15.7 M) | (21.4 M) | (31.9 M) | (36 M) | (39 M) | (29.2 M) | (21.6 M) | (29.9 M) | (41.3 M) | (43.4 M) | (105.2 M) | 1 M | 939.6 K | 986.6 K |
| SHLTN | 1.4 M | 4 M | (7.3 M) | 2.2 M | 829 K | (16.6 M) | (11.1 M) | 2.4 M | 10.1 M | 5.7 M | 278 K | (14.1 M) | (76 K) | (7.1 M) | (28.1 M) | (25.3 M) | (24 M) |
| NWRN | (14.9 M) | (6.4 M) | (2.4 M) | (7.1 M) | (10.1 M) | (22.8 M) | (15.2 M) | (5.3 M) | (15 M) | (20.2 M) | (21 M) | (14.9 M) | (17.5 M) | (16.2 M) | 15.8 M | 18.2 M | 19.1 M |
| DOCM | 3.9 M | 8.7 M | 6.2 M | (15.5 M) | 7.2 M | 3.4 M | (12.8 M) | (36.2 M) | (39 M) | (52.4 M) | (135.7 M) | (225.7 M) | (171.1 M) | 82.3 M | (97.3 M) | (87.5 M) | (83.2 M) |
Molecular Partners and related stocks such as Santhera Pharmaceuticals, Ascom Holding AG, and Addex Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Molecular Partners financial statement analysis. It represents the amount of money remaining after all of Molecular Partners AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Molecular Partners AG | MOLN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Wagistrasse 14, Schlieren, |
| Exchange | SIX Swiss Exchange |
CHF 3.6
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.